Malignancies during the follow-up period after PBSC donation
| Interval after PBPC donation/localization . | Sex/age, y . | Incidence in Germany (per 100 000/y) . | Crude rate . | SIR . | 95% CI . |
|---|---|---|---|---|---|
| 6 mo | |||||
| Malignant melanoma | Male/49 | 13.95 | 12.14 | 1.14 | 0.03-6.36 |
| 12 mo | |||||
| Neuroendocrine carcinoma of unknown primary localization | Male/33 | 1-1.56 | 12.14 | No data available | |
| 24 mo | |||||
| Adenocarcinoma of rectum | Male/57 | 130.55 | 12.14 | 1.21 | 0.04-6.73 |
| Breast cancer | Female/44 | 105.45 | 39.61 | 0.67 | 0.02-3.75 |
| Hodgkin disease | Male/38 | 2.45 | 24.28 | 8.86 | 1.06-31.98* |
| Hodgkin disease | Male/49 | 2.35 | 24.28 | 8.86 | 1.06-31.98* |
| Testicular carcinoma | Male/39 | 305 | 35.01 | 1.61 | 0.19-5.81 |
| Brain tumor | Male/40 | 4.187 | 12.14 | No data available | |
| AML | Male/35 | 1.08 | 12.14 | 11.13 | 0.33-61.89 |
| 36 mo | |||||
| CLL | Female/43 | 39 | 12.14 | 23.33 | 0.70-129.93 |
| Seminoma | Male/41 | 255 | 35.01 | 1.61 | 0.19-5.81 |
| 48 mo | |||||
| Malignancy of unknown origin | Male/58 | Not applicable |
| Interval after PBPC donation/localization . | Sex/age, y . | Incidence in Germany (per 100 000/y) . | Crude rate . | SIR . | 95% CI . |
|---|---|---|---|---|---|
| 6 mo | |||||
| Malignant melanoma | Male/49 | 13.95 | 12.14 | 1.14 | 0.03-6.36 |
| 12 mo | |||||
| Neuroendocrine carcinoma of unknown primary localization | Male/33 | 1-1.56 | 12.14 | No data available | |
| 24 mo | |||||
| Adenocarcinoma of rectum | Male/57 | 130.55 | 12.14 | 1.21 | 0.04-6.73 |
| Breast cancer | Female/44 | 105.45 | 39.61 | 0.67 | 0.02-3.75 |
| Hodgkin disease | Male/38 | 2.45 | 24.28 | 8.86 | 1.06-31.98* |
| Hodgkin disease | Male/49 | 2.35 | 24.28 | 8.86 | 1.06-31.98* |
| Testicular carcinoma | Male/39 | 305 | 35.01 | 1.61 | 0.19-5.81 |
| Brain tumor | Male/40 | 4.187 | 12.14 | No data available | |
| AML | Male/35 | 1.08 | 12.14 | 11.13 | 0.33-61.89 |
| 36 mo | |||||
| CLL | Female/43 | 39 | 12.14 | 23.33 | 0.70-129.93 |
| Seminoma | Male/41 | 255 | 35.01 | 1.61 | 0.19-5.81 |
| 48 mo | |||||
| Malignancy of unknown origin | Male/58 | Not applicable |
SIR indicates standardized incidence ratio; and CI, confidence interval.